CD274 and adenocarcinoma: Based on the positive results of KEYNOTE-189 and KEYNOTE-407, the combination treatment of chemotherapy and pembrolizumab was approved for the first treatment of advanced adenocarcinoma and squamous cell carcinoma of NSCLC, especially for those with negative or low expressions of PD-L1.